197 related articles for article (PubMed ID: 30110619)
1. Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells.
Pereira I; Sousa F; Kennedy P; Sarmento B
Int J Pharm; 2018 Oct; 549(1-2):397-403. PubMed ID: 30110619
[TBL] [Abstract][Full Text] [Related]
2. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
4. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
5. Pegylated polyelectrolyte nanoparticles containing paclitaxel as a promising candidate for drug carriers for passive targeting.
Szczepanowicz K; Bzowska M; Kruk T; Karabasz A; Bereta J; Warszynski P
Colloids Surf B Biointerfaces; 2016 Jul; 143():463-471. PubMed ID: 27037784
[TBL] [Abstract][Full Text] [Related]
6. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel.
Angelopoulou A; Voulgari E; Diamanti EK; Gournis D; Avgoustakis K
Eur J Pharm Biopharm; 2015 Jun; 93():18-26. PubMed ID: 25817600
[TBL] [Abstract][Full Text] [Related]
7. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics.
Tekade RK; Tekade M; Kumar M; Chauhan AS
Pharm Res; 2015 Mar; 32(3):910-28. PubMed ID: 25205461
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy.
Han J; Michel AR; Lee HS; Kalscheuer S; Wohl A; Hoye TR; McCormick AV; Panyam J; Macosko CW
Mol Pharm; 2015 Dec; 12(12):4329-35. PubMed ID: 26505116
[TBL] [Abstract][Full Text] [Related]
9. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
[TBL] [Abstract][Full Text] [Related]
10. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
11. Characterization and in-vitro bioactivity evaluation of paclitaxel-loaded polyester nanoparticles.
López-Gasco P; Iglesias I; Benedí J; Lozano R; Blanco MD
Anticancer Drugs; 2012 Oct; 23(9):947-58. PubMed ID: 22713593
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
13. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability.
Badran MM; Alomrani AH; Harisa GI; Ashour AE; Kumar A; Yassin AE
Biomed Pharmacother; 2018 Oct; 106():1461-1468. PubMed ID: 30119220
[TBL] [Abstract][Full Text] [Related]
14. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
[TBL] [Abstract][Full Text] [Related]
16. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel.
Muntimadugu E; Kumar R; Saladi S; Rafeeqi TA; Khan W
Colloids Surf B Biointerfaces; 2016 Jul; 143():532-546. PubMed ID: 27045981
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel controlled delivery using a pH-responsive functional-AuNP/block-copolymer vesicular nanocarrier composite system.
Liaskoni A; Angelopoulou A; Voulgari E; Popescu MT; Tsitsilianis C; Avgoustakis K
Eur J Pharm Sci; 2018 May; 117():177-186. PubMed ID: 29477643
[TBL] [Abstract][Full Text] [Related]
18. PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.
Emami J; Maghzi P; Hasanzadeh F; Sadeghi H; Mirian M; Rostami M
Pharm Dev Technol; 2018 Jan; 23(1):41-54. PubMed ID: 28608760
[TBL] [Abstract][Full Text] [Related]
19. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.
Sawant RR; Sawant RM; Torchilin VP
Eur J Pharm Biopharm; 2008 Sep; 70(1):51-7. PubMed ID: 18583114
[TBL] [Abstract][Full Text] [Related]
20. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
